PKS Advisory Services LLC Purchases Shares of 12,195 Pfizer Inc. (NYSE:PFE)

PKS Advisory Services LLC acquired a new position in shares of Pfizer Inc. (NYSE:PFE) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 12,195 shares of the biopharmaceutical company’s stock, valued at approximately $324,000.

Other large investors also recently made changes to their positions in the company. Zions Bancorporation N.A. increased its stake in shares of Pfizer by 3.6% during the 4th quarter. Zions Bancorporation N.A. now owns 212,680 shares of the biopharmaceutical company’s stock worth $5,642,000 after purchasing an additional 7,374 shares during the last quarter. Modern Wealth Management LLC increased its position in Pfizer by 48.7% during the fourth quarter. Modern Wealth Management LLC now owns 42,336 shares of the biopharmaceutical company’s stock worth $1,095,000 after buying an additional 13,865 shares during the last quarter. Segall Bryant & Hamill LLC raised its stake in Pfizer by 4.3% in the fourth quarter. Segall Bryant & Hamill LLC now owns 76,539 shares of the biopharmaceutical company’s stock valued at $2,031,000 after buying an additional 3,177 shares during the period. CoreFirst Bank & Trust acquired a new stake in shares of Pfizer in the fourth quarter valued at approximately $226,000. Finally, Barnett & Company Inc. boosted its stake in shares of Pfizer by 4.3% during the 4th quarter. Barnett & Company Inc. now owns 222,898 shares of the biopharmaceutical company’s stock worth $5,913,000 after acquiring an additional 9,273 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the subject of several research reports. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Citigroup cut their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Bank of America reiterated a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. UBS Group cut their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Finally, Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a report on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, six have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $31.92.

Insider Buying and Selling

In related news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is owned by corporate insiders.

Pfizer Stock Performance

Pfizer stock opened at $25.56 on Wednesday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock has a market cap of $144.96 billion, a PE ratio of 18.13, a P/E/G ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The business’s 50-day moving average price is $26.14 and its two-hundred day moving average price is $27.00.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. During the same period in the prior year, the company earned $0.10 EPS. The firm’s quarterly revenue was up 24.7% compared to the same quarter last year. As a group, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.